Last reviewed · How we verify

Higroton® Laboratório Novartis

Eurofarma Laboratorios S.A. · Phase 3 active Small molecule

Higroton® Laboratório Novartis is a Thiazide-like diuretic Small molecule drug developed by Eurofarma Laboratorios S.A.. It is currently in Phase 3 development for Hypertension, Edema associated with congestive heart failure or renal disease.

Higroton (chlorthalidone) is a thiazide-like diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, promoting urinary excretion and reducing blood volume and blood pressure.

Higroton (chlorthalidone) is a thiazide-like diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, promoting urinary excretion and reducing blood volume and blood pressure. Used for Hypertension, Edema associated with congestive heart failure or renal disease.

At a glance

Generic nameHigroton® Laboratório Novartis
SponsorEurofarma Laboratorios S.A.
Drug classThiazide-like diuretic
TargetSodium-chloride cotransporter (NCC)
ModalitySmall molecule
Therapeutic areaCardiovascular
PhasePhase 3

Mechanism of action

Chlorthalidone works by blocking the sodium-chloride cotransporter in the kidney's distal convoluted tubule, preventing electrolyte reabsorption and increasing urine output. This reduces circulating blood volume and total peripheral resistance, leading to decreased blood pressure. It also has mild vasodilatory properties that contribute to its antihypertensive effect.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Higroton® Laboratório Novartis

What is Higroton® Laboratório Novartis?

Higroton® Laboratório Novartis is a Thiazide-like diuretic drug developed by Eurofarma Laboratorios S.A., indicated for Hypertension, Edema associated with congestive heart failure or renal disease.

How does Higroton® Laboratório Novartis work?

Higroton (chlorthalidone) is a thiazide-like diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, promoting urinary excretion and reducing blood volume and blood pressure.

What is Higroton® Laboratório Novartis used for?

Higroton® Laboratório Novartis is indicated for Hypertension, Edema associated with congestive heart failure or renal disease.

Who makes Higroton® Laboratório Novartis?

Higroton® Laboratório Novartis is developed by Eurofarma Laboratorios S.A. (see full Eurofarma Laboratorios S.A. pipeline at /company/eurofarma-laboratorios-s-a).

What drug class is Higroton® Laboratório Novartis in?

Higroton® Laboratório Novartis belongs to the Thiazide-like diuretic class. See all Thiazide-like diuretic drugs at /class/thiazide-like-diuretic.

What development phase is Higroton® Laboratório Novartis in?

Higroton® Laboratório Novartis is in Phase 3.

What are the side effects of Higroton® Laboratório Novartis?

Common side effects of Higroton® Laboratório Novartis include Hypokalemia, Hyperuricemia, Hyperglycemia, Hyponatremia, Dizziness, Headache.

What does Higroton® Laboratório Novartis target?

Higroton® Laboratório Novartis targets Sodium-chloride cotransporter (NCC) and is a Thiazide-like diuretic.

Related